Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Galapagos gains on RA deal

Galapagos (Euronext:GLPG; LSE:GLPG) gained EUR 1.14 (17%) to EUR 7.94 after it partnered with Johnson & Johnson (JNJ) to discover, develop

Read the full 217 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE